Epizyme Inc. appointed Michael Giordano to the board.
Most recently, Giordano was senior vice president and head of development of oncology and immuno-oncology for Bristol-Myers Squibb Co.
Epizyme appoints board member
A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research
2021 Year in Review: Highlighting Key Investment Banking Trends
Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings
Global M&A By the Numbers: Q3 2021
Epizyme Inc. appointed Michael Giordano to the board.
Most recently, Giordano was senior vice president and head of development of oncology and immuno-oncology for Bristol-Myers Squibb Co.